Empirical Asset Management LLC Purchases 459 Shares of Medpace Holdings, Inc. $MEDP

Empirical Asset Management LLC increased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 29.9% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,993 shares of the company’s stock after buying an additional 459 shares during the quarter. Empirical Asset Management LLC’s holdings in Medpace were worth $626,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Geneos Wealth Management Inc. grew its holdings in shares of Medpace by 64.9% during the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock worth $29,000 after buying an additional 37 shares in the last quarter. Brooklyn Investment Group grew its holdings in shares of Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company’s stock worth $30,000 after buying an additional 71 shares in the last quarter. Whittier Trust Co. grew its holdings in shares of Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company’s stock worth $33,000 after buying an additional 35 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of Medpace during the first quarter worth about $60,000. Finally, IFP Advisors Inc grew its holdings in shares of Medpace by 223.3% during the second quarter. IFP Advisors Inc now owns 194 shares of the company’s stock worth $61,000 after buying an additional 134 shares in the last quarter. 77.98% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on MEDP. Cowen cut Medpace from a “buy” rating to a “sell” rating in a research report on Wednesday, July 23rd. TD Cowen reissued a “sell” rating and set a $366.00 price target (up from $283.00) on shares of Medpace in a research report on Wednesday, July 23rd. UBS Group cut Medpace from a “neutral” rating to a “sell” rating and increased their price target for the company from $300.00 to $305.00 in a research report on Tuesday, July 29th. Barclays increased their price target on Medpace from $300.00 to $450.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 23rd. Finally, Zacks Research cut Medpace from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 22nd. Two research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average target price of $424.10.

Medpace Stock Up 1.3%

MEDP opened at $521.21 on Friday. Medpace Holdings, Inc. has a 12-month low of $250.05 and a 12-month high of $547.15. The stock has a market cap of $14.64 billion, a price-to-earnings ratio of 38.75, a PEG ratio of 3.23 and a beta of 1.40. The business has a 50 day moving average of $490.36 and a 200-day moving average of $380.24.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The company had revenue of $603.31 million during the quarter, compared to analysts’ expectations of $537.70 million. During the same period last year, the firm posted $2.75 earnings per share. The business’s revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. As a group, analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Insider Activity at Medpace

In other news, President Jesse J. Geiger sold 41,801 shares of the stock in a transaction that occurred on Thursday, July 24th. The stock was sold at an average price of $453.11, for a total transaction of $18,940,451.11. Following the transaction, the president owned 36,503 shares in the company, valued at approximately $16,539,874.33. This trade represents a 53.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO August J. Troendle sold 48,487 shares of the stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $451.69, for a total value of $21,901,093.03. Following the transaction, the chief executive officer owned 962,615 shares in the company, valued at approximately $434,803,569.35. This trade represents a 4.80% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 161,266 shares of company stock valued at $74,111,427 in the last 90 days. Corporate insiders own 20.30% of the company’s stock.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.